Enzene Biosciences launches its first manufacturing base in the US
Manufactured using Enzene Biosciences’ patented Continuous Manufacturing Process, Bevacizumab is a biosimilar to Avastin and will be available through a non-exclusive partnership for pharmaceutical firms in India
Enzene Biosciences, a unit of India’s Alkem Laboratories, has unveiled plans to open a $50 million manufacturing facility near Princeton, New Jersey. The CDMO expects to hire as many as 300 new workers to support operations at the facility.
An Indian manufacturer will establish its first location outside the Indian subcontinent in New Jersey.
Mumbai: Drug maker Lupin on Tuesday said it has inked a strategic pact with Enzene Biosciences to launch biosimilar cetuximab in India for treatment of head and neck cancer.nnnRead more at:nhttps://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lupin-partners-enzene-to-roll-out-biosimilar-cetuximab-here/articleshow/100631029.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
Drug maker Lupin on Tuesday said it has inked a strategic pact with Enzene Biosciences to launch biosimilar cetuximab in India for treatment of head and neck cancer. Pune-based Enzene Biosciences, is the subsidiary of Alkem Laboratories
Cetuximab is a therapeutic chimeric monoclonal antibody that is used as a targeted therapy for metastatic colorectal cancer (mCRC) and cancer of the head and neck
Pune-based Enzene Biosciences, subsidiary of Alkem Laboratories on Thursday said it has begun commercial lsupplies of adalimumab biosimilar used for treating autoimmune disease like rheumatoid arthritis and ankylosis spondylitis.